Purpose. Hypencin, which has already been used as an antidepressant in clinically, has been shown to have potential antiviral and antineoplastic effects. The present study evaluates the clinical potential of hypericin for the treatment of proliferative vitreoretinopathy (PVR). Methods. PVR was induced in pigmented rabbits by intravitreal injection of 50,000 rabbit conjunctival fibroblasts (RCF) after vitrectomy. Subsequently, the eyes received intravitreal injection of either a sham injection (group A, control) or a single hypericin dose of 1 M (group B), 10 fiM (group C) or 100 jiM (group D). The eyes were examined ophthalmoscopically on days 1, 3, 7, 14, and 28 after surgery to evaluate the development and progression of PVR. The eyes were also examined by light microscopy. For the toxicity study, electroretinograms (ERG) and light microscopic analysis were performed 28 days after a single intravitreal injection of 100 U.M and 10 M hypericin. Results. In control eyes, membranes were well established by 7 days and were associated with retinal detachment. A significant inhibition of PVR were seen in group C and D compared with control eyes (P < 0.05). Differences between group A and B were not significant (P > 0.05). The toxicity study demonstrated no significant toxicity to the eye after administration of hypericin. Conclusions. The results suggest that intravitreal injection of hypericin is effective in reducing the incidence of experimental PVR and may have a potential for the treatment of human PVR.
|Journal||Investigative Ophthalmology and Visual Science|
|Publication status||Published - 1997|
All Science Journal Classification (ASJC) codes
- Sensory Systems
- Cellular and Molecular Neuroscience